[8-K] Moleculin Biotech, Inc. Reports Material Event
Moleculin Biotech, Inc. disclosed that it issued a press release reporting its financial results for the quarter ended June 30, 2025 and recent operational highlights. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into the filing.
The 8-K filing itself does not present numerical revenue, profit, cash flow or balance sheet figures; investors must consult the attached press release for detailed results and metrics. The company鈥檚 common stock trades under the ticker MBRX on The NASDAQ Stock Market. The filing also lists an Inline XBRL cover page as Exhibit 104, indicating machine-readable cover data is included with the submission.
Moleculin Biotech, Inc. ha reso noto di aver diffuso un comunicato stampa con i risultati finanziari relativi al trimestre chiuso al 30 giugno 2025 e con gli ultimi aggiornamenti operativi. Il comunicato 猫 allegato al Modulo 8鈥慘 come Exhibit 99.1 ed 猫 incorporato per riferimento nella comunicazione.
Il file 8鈥慘 non riporta valori numerici su ricavi, utili, flussi di cassa o stato patrimoniale; gli investitori devono fare riferimento al comunicato allegato per i risultati dettagliati e le metriche. Le azioni ordinarie della societ脿 sono negoziate con il ticker MBRX sul NASDAQ. La comunicazione indica inoltre una copertina Inline XBRL come Exhibit 104, segnalando che i dati di copertina in formato leggibile dalle macchine sono inclusi nella presentazione.
Moleculin Biotech, Inc. inform贸 que emiti贸 un comunicado de prensa con sus resultados financieros correspondientes al trimestre concluido el 30 de junio de 2025 y con recientes aspectos operativos. El comunicado est谩 adjunto al Formulario 8鈥慘 como Exhibit 99.1 y se incorpora por referencia en la presentaci贸n.
El propio archivo 8鈥慘 no contiene cifras num茅ricas de ingresos, ganancias, flujos de caja ni balances; los inversores deben consultar el comunicado adjunto para obtener resultados y m茅tricas detalladas. Las acciones ordinarias de la compa帽铆a cotizan con el s铆mbolo MBRX en Nasdaq. La presentaci贸n tambi茅n incluye una portada Inline XBRL como Exhibit 104, lo que indica que se adjuntan datos de portada en formato legible por m谩quina.
Moleculin Biotech, Inc.電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴 鞁れ爜 氚� 斓滉芳 鞖挫榿 順勴櫓鞚� 氤搓碃頃橂姅 氤措弰鞛愲毳� 氚滍憸頄堧嫟瓿� 瓿店皽頄堨姷雼堧嫟. 頃措嫻 氤措弰鞛愲電� Exhibit 99.1搿� Form 8鈥慘鞐� 觳秬霅橃柎 鞝滌稖靹滊鞐� 彀戈碃搿� 韽暔霅橃柎 鞛堨姷雼堧嫟.
8鈥慘 鞛愳泊 氍胳劀鞐愲姅 毵れ稖, 鞚挫澋, 順勱笀頋愲 霕愲姅 雽�彀寑臁绊憸鞚� 靾橃箻臧� 鞝滌嫓霅橃柎 鞛堨 鞎婌溂氙�搿� 靸侅劯 瓴瓣臣鞕� 歆�響滊姅 觳秬霅� 氤措弰鞛愲毳� 彀胳“頃挫暭 頃╇媹雼�. 須岇偓鞚� 氤错喌欤茧姅 NASDAQ 歃濌秾瓯半灅靻岇棎靹� 韹办护 MBRX搿� 瓯半灅霅╇媹雼�. 霕愴暅 Inline XBRL 響滌 韼橃澊歆�臧� Exhibit 104搿� 旮办灛霅橃柎 鞛堨柎 旮瓣硠 韺愲弲順� 響滌 雿办澊韯瓣皜 鞝滌稖氍检棎 韽暔霅橃柎 鞛堨潓鞚� 雮橅儉雰呺媹雼�.
Moleculin Biotech, Inc. a annonc茅 avoir publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et des points op茅rationnels r茅cents. Le communiqu茅 est annex茅 au formulaire 8鈥慘 en tant que Exhibit 99.1 et y est incorpor茅 par r茅f茅rence.
Le d茅p么t 8鈥慘 lui鈥憁锚me ne pr茅sente pas de chiffres num茅riques concernant les revenus, les b茅n茅fices, les flux de tr茅sorerie ou le bilan ; les investisseurs doivent consulter le communiqu茅 annex茅 pour obtenir les r茅sultats d茅taill茅s et les indicateurs. Les actions ordinaires de la soci茅t茅 sont cot茅es sous le symbole MBRX sur le NASDAQ. Le d茅p么t mentionne 茅galement une page de couverture Inline XBRL comme Exhibit 104, indiquant que des donn茅es de couverture lisibles par machine sont incluses dans la soumission.
Moleculin Biotech, Inc. gab bekannt, eine Pressemitteilung mit den Finanzergebnissen f眉r das zum 30. Juni 2025 endende Quartal sowie aktuellen betrieblichen Entwicklungen ver枚ffentlicht zu haben. Die Pressemitteilung ist dem Formular 8鈥慘 als Exhibit 99.1 beigef眉gt und durch Verweis Bestandteil der Einreichung.
Die 8鈥慘鈥慐inreichung selbst enth盲lt keine konkreten Zahlen zu Umsatz, Gewinn, Cashflow oder Bilanz; Anleger m眉ssen die beigef眉gte Pressemitteilung f眉r detaillierte Ergebnisse und Kennzahlen heranziehen. Die Stammaktien des Unternehmens werden unter dem Ticker MBRX an der NASDAQ gehandelt. Die Einreichung f眉hrt au脽erdem eine Inline鈥慩BRL鈥慣itelseite als Exhibit 104 auf, was darauf hinweist, dass maschinenlesbare Titeldaten enthalten sind.
- Press release included as Exhibit 99.1, formally incorporating the company announcement into the SEC record
- Inline XBRL cover page (Exhibit 104) is provided, supporting machine-readable filing data
- No numerical financial figures are presented in the 8-K text; the filing points readers to Exhibit 99.1 for results
- No operational detail or line-item metrics are included within the 8-K itself
Insights
TL;DR: Form 8-K attaches a press release with Q2 2025 results; the 8-K text contains no numerical financial data.
The filing formally incorporates a press release announcing financial results for the quarter ended June 30, 2025 and operational highlights by reference to Exhibit 99.1. No revenue, net income, EPS, cash position or other line-item financials are presented within the 8-K itself, so material financial detail must be obtained from the press release. Inclusion of Exhibit 104 (Inline XBRL cover page) suggests standardized cover-page data accompanies the submission.
TL;DR: Routine disclosure filing to make an earnings press release part of the SEC record; not itself a standalone earnings statement.
The document is a procedural Form 8-K that attaches and incorporates a press release reporting quarter-end results and recent operational highlights. The filing lists two exhibits: 99.1 (press release) and 104 (Inline XBRL cover page). The 8-K provides reference to source materials rather than presenting standalone financial statements, consistent with routine earnings-related disclosures.
Moleculin Biotech, Inc. ha reso noto di aver diffuso un comunicato stampa con i risultati finanziari relativi al trimestre chiuso al 30 giugno 2025 e con gli ultimi aggiornamenti operativi. Il comunicato 猫 allegato al Modulo 8鈥慘 come Exhibit 99.1 ed 猫 incorporato per riferimento nella comunicazione.
Il file 8鈥慘 non riporta valori numerici su ricavi, utili, flussi di cassa o stato patrimoniale; gli investitori devono fare riferimento al comunicato allegato per i risultati dettagliati e le metriche. Le azioni ordinarie della societ脿 sono negoziate con il ticker MBRX sul NASDAQ. La comunicazione indica inoltre una copertina Inline XBRL come Exhibit 104, segnalando che i dati di copertina in formato leggibile dalle macchine sono inclusi nella presentazione.
Moleculin Biotech, Inc. inform贸 que emiti贸 un comunicado de prensa con sus resultados financieros correspondientes al trimestre concluido el 30 de junio de 2025 y con recientes aspectos operativos. El comunicado est谩 adjunto al Formulario 8鈥慘 como Exhibit 99.1 y se incorpora por referencia en la presentaci贸n.
El propio archivo 8鈥慘 no contiene cifras num茅ricas de ingresos, ganancias, flujos de caja ni balances; los inversores deben consultar el comunicado adjunto para obtener resultados y m茅tricas detalladas. Las acciones ordinarias de la compa帽铆a cotizan con el s铆mbolo MBRX en Nasdaq. La presentaci贸n tambi茅n incluye una portada Inline XBRL como Exhibit 104, lo que indica que se adjuntan datos de portada en formato legible por m谩quina.
Moleculin Biotech, Inc.電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴 鞁れ爜 氚� 斓滉芳 鞖挫榿 順勴櫓鞚� 氤搓碃頃橂姅 氤措弰鞛愲毳� 氚滍憸頄堧嫟瓿� 瓿店皽頄堨姷雼堧嫟. 頃措嫻 氤措弰鞛愲電� Exhibit 99.1搿� Form 8鈥慘鞐� 觳秬霅橃柎 鞝滌稖靹滊鞐� 彀戈碃搿� 韽暔霅橃柎 鞛堨姷雼堧嫟.
8鈥慘 鞛愳泊 氍胳劀鞐愲姅 毵れ稖, 鞚挫澋, 順勱笀頋愲 霕愲姅 雽�彀寑臁绊憸鞚� 靾橃箻臧� 鞝滌嫓霅橃柎 鞛堨 鞎婌溂氙�搿� 靸侅劯 瓴瓣臣鞕� 歆�響滊姅 觳秬霅� 氤措弰鞛愲毳� 彀胳“頃挫暭 頃╇媹雼�. 須岇偓鞚� 氤错喌欤茧姅 NASDAQ 歃濌秾瓯半灅靻岇棎靹� 韹办护 MBRX搿� 瓯半灅霅╇媹雼�. 霕愴暅 Inline XBRL 響滌 韼橃澊歆�臧� Exhibit 104搿� 旮办灛霅橃柎 鞛堨柎 旮瓣硠 韺愲弲順� 響滌 雿办澊韯瓣皜 鞝滌稖氍检棎 韽暔霅橃柎 鞛堨潓鞚� 雮橅儉雰呺媹雼�.
Moleculin Biotech, Inc. a annonc茅 avoir publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et des points op茅rationnels r茅cents. Le communiqu茅 est annex茅 au formulaire 8鈥慘 en tant que Exhibit 99.1 et y est incorpor茅 par r茅f茅rence.
Le d茅p么t 8鈥慘 lui鈥憁锚me ne pr茅sente pas de chiffres num茅riques concernant les revenus, les b茅n茅fices, les flux de tr茅sorerie ou le bilan ; les investisseurs doivent consulter le communiqu茅 annex茅 pour obtenir les r茅sultats d茅taill茅s et les indicateurs. Les actions ordinaires de la soci茅t茅 sont cot茅es sous le symbole MBRX sur le NASDAQ. Le d茅p么t mentionne 茅galement une page de couverture Inline XBRL comme Exhibit 104, indiquant que des donn茅es de couverture lisibles par machine sont incluses dans la soumission.
Moleculin Biotech, Inc. gab bekannt, eine Pressemitteilung mit den Finanzergebnissen f眉r das zum 30. Juni 2025 endende Quartal sowie aktuellen betrieblichen Entwicklungen ver枚ffentlicht zu haben. Die Pressemitteilung ist dem Formular 8鈥慘 als Exhibit 99.1 beigef眉gt und durch Verweis Bestandteil der Einreichung.
Die 8鈥慘鈥慐inreichung selbst enth盲lt keine konkreten Zahlen zu Umsatz, Gewinn, Cashflow oder Bilanz; Anleger m眉ssen die beigef眉gte Pressemitteilung f眉r detaillierte Ergebnisse und Kennzahlen heranziehen. Die Stammaktien des Unternehmens werden unter dem Ticker MBRX an der NASDAQ gehandelt. Die Einreichung f眉hrt au脽erdem eine Inline鈥慩BRL鈥慣itelseite als Exhibit 104 auf, was darauf hinweist, dass maschinenlesbare Titeldaten enthalten sind.
|
|
|
|
|
(State or Other Jurisdiction of Incorporation
or Organization)
|
(Commission File No.) | (I.R.S. Employer Identification No.) |
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Exhibit
No.
|
Description |
| 99.1 | Press Release dated August 13, 2025 |
| 104 | Cover page Interactive Data File (embedded within the Inline XBRL document) |
|
MOLECULIN BIOTECH, INC.
|
|||
| Date: August 13, 2025 | |||
|
By:
|
/s/ Jonathan P. Foster
|
||
|
Jonathan P. Foster
|
|||
|
Chief Financial Officer
|
|||
Source:
FAQ
What did Moleculin Biotech (MBRX) disclose in this 8-K?
Does the Form 8-K include the company鈥檚 financial statements or numeric results?
Which exhibits are attached to the filing?
What exchange and ticker does the filing identify for Moleculin Biotech?
Who signed the Form 8-K on behalf of the company?
